Physician profile
Gilberto Lopes
NPI 1912350596
$99,156.57
in general payments reported to CMS, 2019-2025
29 companies · $29K in 2025
The $29K reported for 2025 was more than what 91% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60.55 · 2020: $5,826 · 2021: $6,500 · 2022: $17K · 2023: $11K · 2024: $31K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $42K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Honoraria: $4,110 · Travel and Lodging: $1,411 · Food and Beverage: $871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $41,819.28 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,980.00 |
| Honoraria | $4,110.00 |
| Travel and Lodging | $1,411.00 |
| Food and Beverage | $871.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Uk Limited | $25,345.00 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $19,447.49 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $14,137.66 | 2022-2025 | Tagrisso |
| Dr.Reddy'S Laboratories,INC. | $9,750.00 | 2022-2025 | |
| Mirati Therapeutics, INC. | $6,622.88 | 2023 | Krazati |
| Rigel Pharmaceuticals, INC. | $5,887.48 | 2024-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Blueprint Medicines Corporation | $5,320.00 | 2020 | |
| Coherus Oncology, INC. | $4,237.88 | 2021-2023 | |
| Beone Medicines USA, INC. | $3,750.00 | 2025 | |
| Janssen Global Services, LLC | $2,362.50 | 2023-2025 | Rybrevant |
| Regeneron Pharmaceuticals, INC. | $1,654.00 | 2023 | |
| Janssen Biotech, INC. | $203.92 | 2025 | Rybrevant |
| Beigene USA, INC. | $129.87 | 2023 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $120.71 | 2024 | Libtayo |
| Janssen Scientific Affairs, LLC | $98.21 | 2023 | Akeega |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $42.95 | 2019-2020 | |
| Pfizer INC. | $31.48 | 2019 | |
| Celgene Corporation | $14.54 | 2019 |
11 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilberto Lopes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.